Core Insights - Iovance Biotherapeutics, Inc. has appointed Corleen Roche as Chief Financial Officer, effective August 6, 2025, to support its first commercial launch and revenue growth [1][2][3] Company Overview - Iovance Biotherapeutics focuses on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a global leader in this field [1][3] - The company has achieved FDA approval for its T cell therapy, Amtagvi, which is the first of its kind for a solid tumor indication [3] Leadership Experience - Corleen Roche brings over 30 years of experience in the biotech and life sciences industry, having held executive financial leadership roles in several publicly traded companies [2] - Roche's previous positions include CFO of CG Oncology, Immunome, and Biogen, where she successfully prepared for multiple product launches [2] Strategic Focus - The company aims to grow revenue, manage its balance sheet, and advance its mission of developing innovative therapies for solid tumors under Roche's financial leadership [2][3] - Roche expressed commitment to focusing pipeline investments on high-value opportunities while achieving financial goals to build a profitable biotechnology company [3]

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Iovance provided misleadingly positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace in treatment initiation [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug ...

Click here to participate in the action. According to the complaint, throughout the class period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments throu ...

Core Insights - Iovance Biotherapeutics, Inc. announced positive results from a real-world study demonstrating the effectiveness of its TIL therapy, Amtagvi (lifileucel), for patients with advanced melanoma previously treated with immune checkpoint inhibitors [2][3] - The study showed an overall response rate (ORR) of 48.8% among 41 evaluable patients, with a higher ORR of 60.9% in patients who had received two or fewer prior lines of therapy [3][5] - Amtagvi received accelerated approval from the FDA in February 2024, marking it as the first one-time T cell therapy for solid tumors and the first approved treatment for advanced melanoma after anti-PD-1 and targeted therapy [5][12] Company Overview - Iovance Biotherapeutics focuses on developing and delivering innovative TIL therapies for cancer patients, aiming to harness the immune system to target diverse cancer cells [12][14] - The company is conducting a Phase 3 trial, TILVANCE-301, to further confirm the clinical benefits of Amtagvi in frontline advanced melanoma [5][12] Product Information - Amtagvi is indicated for adults with unresectable or metastatic melanoma that has not responded to prior PD-1 blocking therapy and, if applicable, BRAF inhibitors [6][12] - The therapy is derived from the patient's own tumor, which is processed to produce billions of viable T cells for treatment [13]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Iovance Biotherapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, and highlights the potential for compensation without out-of-pocket costs through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Iovance securities between May 9, 2024, and May 8, 2025, may be eligible to join a class action lawsuit [1][2]. - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of its sales team and new Authorized Treatment Centers (ATCs), which resulted in higher costs and lower revenue due to patient drop-offs and delays in treatment initiation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting that many firms may not have the necessary experience or resources [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019, and has been recognized for its success in securities class action settlements [4].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly providing misleading information regarding its growth potential and operational capabilities during the class period from May 9, 2024, to May 8, 2025 [1][3]. Company Performance - Iovance announced its financial results for Q2 of fiscal 2024 on July 25, 2024, and subsequently reduced its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance of its iCTC, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [4]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [4]. Legal Context - The class action lawsuit is on behalf of all individuals and entities that purchased Iovance securities during the specified class period, with a deadline of July 14, 2025, for investors to apply to be appointed as lead plaintiff [1]. - The lawsuit claims that the company made overwhelmingly positive statements while concealing material adverse facts about its ability to meet demand for its treatments [3]. Investor Information - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Iovance securities is from May 9, 2024, to May 8, 2025, inclusive [1]. - Investors who purchased Iovance securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 14, 2025 [2]. Group 2: Allegations Against Iovance - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi [3]. - It is claimed that the sales team and new ATCs were ineffective in patient identification and selection, leading to higher patient drop-offs [3]. - These issues resulted in increased costs and lower revenue, as ATCs could not keep pace with the manufactured product, contradicting the positive statements made by the defendants about Iovance's business and prospects [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation aligns with his executive employment agreement and comes at a critical time for the company [2] - The company has not yet appointed a successor for the CFO position, creating uncertainty as it faces market and legal challenges [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has significantly underperformed, leading to a downward revision of the company's full-year revenue projections [3][6] - The first-quarter sales figures for Amtagvi fell short of Wall Street expectations, prompting a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is facing a class-action securities fraud lawsuit related to its claims about authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5] - The lawsuit alleges discrepancies between the company's public statements about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [7]

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, which is administered at authorized treatment centers (ATCs) [3]. Group 2: Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Group 3: Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].